viernes, 6 de marzo de 2026

Sociodemographic and Clinical Characteristics of Diabetic Patients with Peripheral Arterial Disease In 2 Centers

Sociodemographic and Clinical Characteristics of Diabetic Patients with Peripheral Arterial Disease In 2 Centers

Emad Ahmed Hussein (1), Hala Ahmed Talkhan (2), Mohamed Farouk Allam (3)*, Amr Nabil Kamel (1), Marwa Rushdy Elnajjar (2), Mohamed Mahmoud Zaki (1)

 

1. Department of Vascular Surgery, Ain Shams University, Cairo, Egypt.

2. Department of Clinical Pathology, Ain Shams University, Cairo, Egypt.

3. Department of Family Medicine Faculty of Medicine, Ain Shams University 11566 Abbasia, Cairo, Egypt.

 

DOI: 10.21608/asmj.2025.360251.1391

 

Abstract

Background: Comparing revascularization outcomes between the UK and Egypt helps identify clinical differences, outcome predictors, and healthcare disparities, guiding context-specific management for diabetic patients with peripheral arterial disease (PAD). Aim: This study aimed to assess the clinical characteristics, outcomes, and predictors among patients undergoing revascularization in two tertiary centres. Methods: From March 2019 to December 2021, diabetic PAD patients undergoing revascularization were recruited from Royal Free Hospital (RFH), London, UK, and Ain Shams University Hospitals (ASUHs), Cairo, Egypt. Due to the COVID-19 pandemic, only 43 patients were included—17 from RFH and 26 from ASUHs—and followed for 3 months post-procedure. Sociodemographic data, medical history, and outcomes were collected. Egyptian patients also underwent pre- and postoperative testing for vascular inflammatory biomarkers: hsCRP, D-dimer, fibrinogen, Cystatin C, and LDL. Results: RFH patients were significantly older than ASUHs patients (70.1 vs. 60.5 years, p=0.004). Most were male (82.4% RFH, 84.6% ASUHs). ASUHs patients had higher rates of smoking (65.4% vs. 35.3%), obesity (50% vs. 11.8%, p=0.01), and hypercholesterolemia (76.9% vs. 17.6%, p=0.000). RFH patients had more renal insufficiency (58.8% vs. 3.8%, p=0.000) and foot ulcers (82.4% vs. 39.5%, p=0.006). Despite differences, favourable outcomes were similar (82.4% RFH vs. 88.5% ASUHs). Among ASUHs patients, postoperative reductions in LDL (p=0.03) and Cystatin C (p=0.13) were associated with better outcomes. Conclusion: ASUHs patients were younger and had different risk profiles, but clinical outcomes were comparable. Biomarker changes may help predict post-revascularization recovery.

 

Keywords: Diabetes mellitus, endovascular treatment, hypertension, hypercholesterolemia, obesity, peripheral arterial disease, surgical revascularization, smoking, Royal Free University Hospitals, Ain Shams University Hospitals, Egypt, UK.

 

https://asmj.journals.ekb.eg/article_487106.html

domingo, 15 de febrero de 2026

Tunis 2026: Shaping a New Era of Patient-Centered Respiratory Care in North Africa

 Tunis 2026: Shaping a New Era of Patient-Centered Respiratory Care in North Africa

The North African Respiratory Interdisciplinary Forum is more than a medical meeting—it marks the beginning of a transformative new era in respiratory patient care across the region.

Our mission is to place the patient at the heart of care.

The International Primary Care Respiratory Group (IPCRG) has developed a robust suite of tools for primary care that now serve as foundational pillars of this new model. The Forum’s educational approach is inspired by contemporary pedagogical methods. Innovative formats such as the Inhaler Game, World Café, and Escape Room create engaging, interactive learning experiences that go beyond traditional lectures.

We warmly invite you to take part in this dynamic shift in respiratory care by participating in the North African Respiratory Interdisciplinary Forum.

 

The programme and website

https://ipcrg2026.org/index.php/scientific-programme/

 

Abstract submission

https://www.ipcrg.org/tunis-2026-8-reasons-to-submit-an-abstract-before-22-february

sábado, 7 de febrero de 2026

Psorisbye: Psoriasis, Atopic Dermatitis and Otic Eczema

Psorisbye: Psoriasis, Atopic Dermatitis and Otic Eczema

 

Innovation in healthcare is built on research, evidence, and intellectual property protection. Our topical therapy development is supported by an invention patent approved by the Spanish Ministry of Industry, Trade and Tourism (Ref. 202030824, granted on February 14, 2023).

 

This work is the result of the research group led by José Miguel Ingelmo Calvo, José Ruiz Cobo, and Mohamed Farouk Allam, and has been reinforced by multiple peer-reviewed scientific publications in the field of dermatology between 2023 and 2024.

 

1- José Miguel Ingelmo Calvo, José Ruiz Cobo, Mohamed Farouk Allam. New Topical Treatment for Psoriasis: A Case Report. Journal of Exploratory Research in Pharmacology 2023;8(3):263-265. https://doi.org/10.14218/JERP.2023.00015         

2- José Miguel Ingelmo Calvo, José Ruiz Cobo, Mohamed Farouk Allam. A Report of Three Cases with Moderate Psoriasis Treated with New Topical Treatment. Global Journal of Medical Case Reports 2023;3(1):16-20. https://doi.org/10.31586/gjmcr.2023.714

3- José Miguel Ingelmo Calvo, José Ruiz Cobo, Mohamed Farouk Allam. NewTopical Treatment for Atopic Dermatitis. European Journal of Medical and Health Sciences 2024;6(2):17-19. https://doi.org/10.24018/ejmed.2024.6.2.2067

4- José Miguel Ingelmo Calvo, José Ruiz Cobo, Mohamed Farouk Allam. New Topical Therapy for Moderate Psoriasis: An Open-Label, Pilot Study. International Journal of Pharmaceutical and Phytopharmacological Research 2024;14(2):31-4. https://doi.org/10.51847/8b1eX1xZRO

5- José Miguel Ingelmo Calvo, José Ruiz Cobo, Mohamed Farouk Allam. Innovative Topical Therapy for Otic Eczema. European Journal of Clinical Medicine 2024;5(3):1-2. https://doi.org/10.24018/clinicmed.2024.5.3.334

6- José Miguel Ingelmo Calvo, José Ruiz Cobo, Mohamed Farouk Allam. Innovative Topical Therapy for Extensive Psoriasis: A New Approach to Treatment. European Journal of Medical and Health Sciences 2024;6(6):6-8. http://dx.doi.org/10.24018/ejmed.2024.6.6.2200